J2S-MC-GZMT
Research type
Research Study
Full title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants with IBS-C
IRAS ID
1013823
Contact name
Tetiana Rudenok
Contact email
Sponsor organisation
Eli Lilly and Company
Research summary
This study aims to evaluate whether an investigational medicine called brenipatide is safe and effective for people who have irritable bowel syndrome-constipation (IBS-C). The study will compare several doses of brenipatide with a placebo, which is pharmacologically inactive substance.
Participants may take part in the study for up to approximately 35 weeks. This includes a screening period of up to 3 weeks, a 24-week treatment period, and a safety follow up period of around 8 weeks after the last dose or if treatment is stopped early.
The results of this study will help researchers understand whether brenipatide could be a future treatment option for people with IBS-C.REC name
East of England - Essex Research Ethics Committee
REC reference
26/EE/0089
Date of REC Opinion
7 May 2026
REC opinion
Further Information Favourable Opinion